Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 4/20 | 0.31 |
| ▸ | CA9 | Q16790 | 4/20 | 0.31 |
| ▸ | NAAA | Q02083 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11042820 | 0.98 | EPHX1 (0.35) | CHRM2CHRM1CHRM4CHRM3SLC18A3 | |
| SCHEMBL1930310 | 0.94 | — | — | |
| SCHEMBL1928265 | 0.87 | — | — | |
| SCHEMBL2541143 | 0.80 | CA12 (0.40) | CHRM2CHRM1CHRM4CHRM3SLC18A3 | |
| SCHEMBL2541139 | 0.80 | CA12 (0.40) | CHRM2CHRM1CHRM4CHRM3SLC18A3 | |
| SCHEMBL3678451 | 0.80 | RAB9A (0.33) | CHRM2CHRM1CHRM4CHRM3SLC18A3 | |
| SCHEMBL3674322 | 0.79 | CA12 (0.34) | CHRM2CHRM1CHRM4CHRM3SLC18A3 | |
| SCHEMBL3674320 | 0.79 | CA12 (0.34) | CHRM2CHRM1CHRM4CHRM3SLC18A3 | |
| SCHEMBL15750117 | 0.79 | CA12 (0.34) | CHRM2CHRM1CHRM4CHRM3SLC18A3 | |
| SCHEMBL2536102 | 0.79 | BCHE (0.33) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191473-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | Esanex, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| WO-2016040809-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | ESANEX, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| US-20190225587-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | ESANEX, INC. | 2019-07-25 | — | — | US | disclosed |
| US-10246421-B2 | Indazolyl- and indolyl-benzamide derivatives | ESANEX, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3191473-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | Esanex, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9708273-B2 | Aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160229813-A1 | ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-11 | — | — | US | disclosed |
| WO-2016040809-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | ESANEX, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20160075662-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | ESANEX, INC. | 2016-03-17 | — | — | US | disclosed |
| US-20150031713-A1 | ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2015-01-29 | — | — | US | disclosed |
| US-8883810-B2 | Aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-4766120-A | ANTIINFLAMMATORY AGENTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1988-08-23 | — | — | US | disclosed |
| US-4663323-A | Tetrazole derivatives, anti-ulcer composition containing the same and method for treating ulcers | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-05-05 | — | — | US | disclosed |
| EP-0035046-B1 | NOVEL TETRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND ANTI-ULCER COMPOSITION CONTAINING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-10-02 | — | — | EP | disclosed |
| US-4540703-A | Tetrazole derivatives, anti-ulcer composition containing the same and method for treating ulcers | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1985-09-10 | — | — | US | disclosed |
| US-4497815-A | 1-(N-Substituted carbamoyl)-5-fluorouracil derivatives and the carcinostatic agents containing same as active ingredients | Ozaki, Shoichiro (JP) | 1985-02-05 | — | — | US | disclosed |
| US-4451471-A | Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same | CIBA-GEIGY CORPORATION (US) | 1984-05-29 | — | — | US | disclosed |
| EP-0061425-A2 | Thiazole derivatives, processes for their preparation, medicaments containing them and their use | CIBA-GEIGY AG (CH) | 1982-09-29 | — | — | EP | disclosed |
| EP-0035046-A1 | Novel tetrazole derivatives, process for the preparation thereof, and anti-ulcer composition containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-09 | — | — | EP | disclosed |
| US-3998827-A | HYPOTENSIVE AGENTS | THE UPJOHN COMPANY (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246421-B2 | Indazolyl- and indolyl-benzamide derivatives | IDO2, MKI67, IDO1 | CHRM2 4676/4885CHRM1 4661/4885CHRM4 4736/4885 |
| US-20190225587-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | IDO2, MKI67, IDO1 | CHRM2 4676/4885CHRM1 4661/4885CHRM4 4736/4885 |
| US-20160075662-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | IDO2, MKI67, IDO1 | CHRM2 4676/4885CHRM1 4661/4885CHRM4 4736/4885 |
| US-20150031713-A1 | ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | CHRM2 6/4885CHRM1 1/4885CHRM4 8/4885 |
| US-20160229813-A1 | ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | CHRM2 6/4885CHRM1 1/4885CHRM4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.